RESEARCH TRIANGLE PARK, NC / January 29, 2024 – Rho, a global, full-service contract research organization (CRO), announces that Rho Federal Systems Division, Inc. will provide Statistical and Data Coordinating (SDCC) services for a clinical trial to evaluate the safety and immunogenicity of vaccines against A(H5) viruses to maximize pandemic influenza preparedness. The trial will be conducted under the Clinical Studies Network and is sponsored by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services.

This trial will enroll healthy participants aged 18 years and older and assess the immunogenicity and safety of different antigen doses of egg-based and recombinant protein-based vaccines in combination with selected adjuvants. The data from this trial will be used to determine potential vaccination strategies in the event of a public health emergency. https://aspr.hhs.gov/AboutASPR/ProgramOffices/BARDA/Pages/default.aspx

“The 1918 H1N1 and the 2020 COVID-19 pandemics were the most severe in modern history and share an interesting trait: both were caused by a virus in its earliest jump from animals to humans. BARDA is working to increase preparedness and understand vaccination strategies for the next influenza pandemic, and A(H5) viruses are a key target,” said Peter Schmidt, Rho’s Chief Scientific Officer. “We are proud to partner with BARDA and leverage the expertise of our scientific, operational, and statistical teams to ensure the success of this important trial.”

As the SDCC, Rho will provide program management, protocol development, medical writing, statistics and data management, pharmacovigilance, safety monitoring, and central data analytical support and development.

This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number 75A50120D00015.

About Rho

Rho is a global, privately held contract research organization (CRO) headquartered in Research Triangle Park, a biotech hub in North Carolina, US. Rho provides a full range of drug development services, from program strategy through to clinical trials and marketing applications. Since 1984, Rho has been a trusted partner to some of the most innovative pharmaceutical, biotechnology and medical device companies as well as academic and government organizations. Dedicated to service excellence and cross-functional collaboration, Rho’s therapeutic expertise, employee focus and commitment to strong site relationships change what it means to work with a CRO – accelerating time to market, maximizing ROI, and delivering consistent, smarter and more efficient programs. Experience Rho by following the company on LinkedIn.

MEDIA CONTACT:
Julie Colman (on behalf of Rho)
LARGEMOUTH COMMUNICATIONS
p: 919.459.6450
rho@largemouthpr.com